Liquidia starts YUTREPIA shipments after FDA approval; court denies UTHR injunction

Liquidia Corp

First commercial shipment of YUTREPIA (treprostinil) inhalation powder to specialty pharmacies scheduled.
FDA approved YUTREPIA on May 23, 2025 for PAH and PH-ILD.
Court denied United Therapeutics' motion for preliminary injunction and TRO on May 30, 2025.
Court concluded UTHR unlikely to succeed on merits; Liquidia's motion to dismiss remains pending.
CEO cites rapid launch: sales force active, product listed with compendia within one week.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.